CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleLevered free cash flow is -$267.22M, lower than 95% of all stocks globally
- FinancialsAltman Z-Score 12.3: safe zone
- Interpretations3 currently firing — 3
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
2.30BUSDvs all stocks (USD)
Revenue (TTM)
66.05MUSDvs all stocks (USD)
Beta
0.5400xvs all stocks
52-Week Change
-1.60%vs all stocks
Market Capitalization
2.30BUSDvs all stocks (USD)
Enterprise Value
1.67BUSDvs all stocks (USD)
Forward P/E
-8.44xvs Biotechnology peers
Price to Sales (TTM)
34.86xvs Biotechnology peers
Price to Book (MRQ)
2.07xvs Biotechnology peers
Enterprise to Revenue
25.28xvs Biotechnology peers
Enterprise to EBITDA
-3.55xvs Biotechnology peers
Gross Margin
93.64%vs Biotechnology peers
Operating Margin
-530.34%vs Biotechnology peers
Return on Assets (TTM)
-21.69%vs Biotechnology peers
Return on Equity (TTM)
-32.81%vs Biotechnology peers
Revenue (TTM)
66.05MUSDvs all stocks (USD)
Revenue per Share (TTM)
1.13USDUpdated Jul 17, 2026Quarterly Revenue Growth
137.70%vs Biotechnology peers
Gross Profit (TTM)
-288.47MUSDvs all stocks (USD)
EBITDA (TTM)
-470.27MUSDvs all stocks (USD)
Net Income (TTM)
-422.60MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
137.75%vs Biotechnology peers
Operating Cash Flow (TTM)
-380.41MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-267.22MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 17, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
54.03MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
6.34MUSDFY2025 · Dec 31, 2025Gross Profit
47.68MUSDFY2025 · Dec 31, 2025Operating Income
-472.13MUSDvs all stocks (USD)
Pre-tax Income
-413.80MUSDFY2025 · Dec 31, 2025Income Tax Expense
-1.02MUSDFY2025 · Dec 31, 2025Net Income
-412.78MUSDFY2025 · Dec 31, 2025EBIT
-472.13MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-466.95MUSDFY2025 · Dec 31, 2025Research & Development
339.54MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
180.28MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
56.38MUSDFY2025 · Dec 31, 2025EPS (Basic)
-7.12USDFY2025 · Dec 31, 2025EPS (Diluted)
-7.12USDFY2025 · Dec 31, 2025Basic Shares Outstanding
57.97MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
57.97MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-412.78MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-360.22MUSDFY2025 · Dec 31, 2025Free Cash Flow
-364.54MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
89.13MUSDFY2025 · Dec 31, 2025Income Tax Paid
628.00KUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-412.78MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
5.18MUSDFY2025 · Dec 31, 2025Stock-based Compensation
52.55MUSDFY2025 · Dec 31, 2025Other Non-cash Items
22.43MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-6.47MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
1.75MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-22.88MUSDFY2025 · Dec 31, 2025Capital Expenditures
-4.32MUSDFY2025 · Dec 31, 2025Net Intangibles (CF)
-10.00MUSDFY2025 · Dec 31, 2025Net Acquisitions
0.00USDFY2025 · Dec 31, 2025Purchase of Investments
-641.76MUSDFY2025 · Dec 31, 2025Sale of Investments
1.03BUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
387.18MUSDFY2025 · Dec 31, 2025Shares Outstanding
59.34MSharesUpdated Jul 17, 2026Float Shares
50.06MSharesUpdated Jul 17, 2026Shares Short
6.76MSharesUpdated Jul 17, 2026Short Ratio
5.64daysvs all stocks
Short % of Shares Outstanding
11.48%vs all stocks
% Held by Insiders
1.12%vs all stocks
% Held by Institutions
109.27%vs all stocks
Total Cash (MRQ)
737.04MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
12.39USDUpdated Jul 17, 2026Total Debt (MRQ)
35.74MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0322xvs Biotechnology peers
Current Ratio (MRQ)
14.19xvs Biotechnology peers
Book Value per Share (MRQ)
18.69USDUpdated Jul 17, 2026Total Assets
1.30BUSDvs all stocks (USD)
Total Current Assets
942.05MUSDFY2025 · Dec 31, 2025Total Liabilities
104.11MUSDFY2025 · Dec 31, 2025Total Non-current Assets
355.17MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
21.91MUSDFY2025 · Dec 31, 2025Total Current Liabilities
82.21MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
89.13MUSDFY2025 · Dec 31, 2025Other Short-term Investments
765.29MUSDFY2025 · Dec 31, 2025Accounts Receivable
10.58MUSDFY2025 · Dec 31, 2025Inventory
32.92MUSDFY2025 · Dec 31, 2025Accounts Payable
18.36MUSDFY2025 · Dec 31, 2025Short-term Debt
18.39MUSDFY2025 · Dec 31, 2025Long-term Debt
21.82MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
90.00KUSDFY2025 · Dec 31, 2025Common Stock (Book)
75.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-561.71MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
1.19BUSDvs all stocks (USD)
Treasury Stock
802.49MUSDFY2025 · Dec 31, 202552-Week Low
22.24USDUpdated Jul 17, 202652-Week High
46.00USDUpdated Jul 17, 202652-Week Change
-1.60%vs all stocks
Beta
0.5400xvs all stocks
50-Day MA
32.19USDUpdated Jul 17, 2026200-Day MA
31.89USDUpdated Jul 17, 2026Avg 10-Day Volume
955.42KSharesUpdated Jul 17, 2026Avg 30-Day Volume
1.13MSharesUpdated Jul 17, 2026Diluted EPS (TTM)
-7.26USDUpdated Jul 17, 2026Other Income / Expense
1.96MUSDFY2025 · Dec 31, 20253 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
How does this company use capital?
Revenue Growing With Receivables Growing
Revenue has risen three years, and what customers owe has risen with it.
Reads
Where is this company structurally exposed?
Partial Recovery After Sharp Decline
A weak, thin-volume bounce inside a decline that is still far from recovered.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 12.3: safe zoneNotable
Altman Z-Score: 12.30
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Levered free cash flow is -$267.22M, lower than 95% of all stocks globallySignificant
Levered free cash flow (USD): -267,222,000Global P5: -219,013,500
Market cap is $2.3B, above the global median of $1.15BNotable
Market cap (USD): 2,302,740,700Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
Nektar Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Jiangzhong Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Biohaven Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Voronoi, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Jiuzhou Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Nanobiotix S.A.
Tier 1ProductionApproval-Gated PipelineRule
Pavella Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Pfizer Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Zensar Technologies Ltd.
2 interpretationsRevenue Growing With Receivables GrowingMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Guangdong Nedfon Air System Co., Ltd.
2 interpretationsPartial Recovery After Sharp DeclineMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Sensorion SA
2 interpretationsPartial Recovery After Sharp DeclineMulti-Year Debt Decrease With Cash Near Total Debt And Equity